The FDA and Human Health Services (HHS) has recently finalized guidance on the written procedures of institutional review boards (IRB). IRBs are dedicated to supervising and approving studies that involve humans, while also maintaining fair and safe treatment of those subjects. Both FDA and HHS regulations state that IRBs must follow the written procedures for the following activities:
- Producing and reviewing original research, in addition to reporting any findings to the investigator and the institution.
- Deciding which research projects have to be completed more than once annually and also verified by parties other than the investigator and the institution.
- Initiating changes to the research methods must be reported to and approved by the IRB.
- Reporting risks, compliance issues or a possible delay or termination of IRB approval of FDA regulated research that is approved by the FDA and HHS to the appropriate IRB, institutional officials and department or agency heads.
This guidance also specifies a 55-item checklist of written procedures to follow. However, it is up to the IRB to determine how they will follow the written procedures given that there is no set composition and content set out by the FDA and HHS.
RegDesk is an A.I.-powered regulatory intelligence software that offers 24/7 access to the latest regulatory information for over 50 markets worldwide. Our platform eliminates the need for medical device companies to spend months gathering intelligence and preparing their registration applications. Through RegDesk’s centralized platform, clients can get access to product-specific registration requirements, expert answers to their most critical regulatory questions, and real-time alerts about global regulatory changes. To experience the power of RegDesk, contact us at email@example.com or visit www.regdesk.co.